OSA, obstructive sleep apnea syndrome
Obstructive sleep apnea syndrome is one of the most common and dangerous diseases associated with sleep disorders. OSA is accompanied by loud snoring, sleep breathing stops for 10 seconds or more, excessive daytime sleepiness. As of early 2019, more than 100 million people worldwide are affected by the disease.
Content |
The main articles are:
In the absence of correct treatment, OSA can provoke various cardiological disorders, increases the risk of stroke. In addition, the danger of getting into an accident and getting industrial injuries increases, irritability, depressive states appear, and there is a decrease in the quality of life in general. It has been proven that the life expectancy of people who do not pay attention to the prevention of this disease is reduced by 15-20 years (data are given in accordance with the DALY index (DALY - the number of lost years of life as a result of premature death, as well as years lived with certain restrictions of health and body functions).
One method of prevention of OSA is CPAP therapy, which keeps the airways open and restores the normal level of oxygen saturation of the body.
2025: A neck-mounted neuromodulator for apnea has entered the market. It is installed without surgery and compatible with MRI
In early August 2024, Nyxoah, based in Mont Saint-Gibert (Belgium), announced the release of the Genio system for the treatment of obstructive sleep apnea. The solution provides for the use of a module attached to the neck. Read more here.
2023
A mouth-sticking device for the treatment of severe apnea has been released
On November 29, 2023, Vivos Therapeutics introduced the CARE series oral devices designed to treat severe obstructive sleep apnea (OSA). These products are an alternative to neurostimulation implants and IPAP therapy - artificial ventilation of the lungs with constant positive pressure. Read more here.
Inspire Medical Systems Gets Approval to Sell Obstructive Sleep Apnea Treatment Device
The company Inspire Medical Systems received American from the regulator () industries health care FDA an expanded permission to use its eponymous, which medical devices for the treatment of obstructive sleep apnea (CSA) should increase the circle of people who can apply such treatment. This became known on June 23, 2023. More. here
See also
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |